If thermogenesis, energy expenditure, and fat oxidation through glucagon signaling are part of your research interest, retatrutide is the only option that provides this in a single molecule
10.1016/j.bbamem.2012.07.032 87 SchelshornD.JolyF.MutelS.HampeC.BretonB.MutelV.et al (2012)
Furthermore, different from the ordered -helical ECL1 in inactive GLP-1R 33 and -hairpin in inactive GCGR 36 that cover the binding pocket and probably block peptide insertion, ECL1 of active GLP-2R, GLP-1R and GCGR simultaneously move outward and stand upwards in line with TM2 and TM3
Food and Drug Administration approved Foundayo (orforglipron) for adults with obesity, or for adults who are overweight and have at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol
However, its use in the general population for weight management or body composition enhancement is not supported by sufficient evidence and falls outside its licensed indications in all countries where it holds authorisation
Published studies have investigated retatrutide as a ligand with activity reported across GLP 1, GIP, and glucagon receptors, with research interest spanning energy balance and glucose regulation pathways
